Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 828137, 6 pages
http://dx.doi.org/10.1155/2014/828137
Research Article

Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study

1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 457-0036, Japan
2Okuda Naika Clinic, 2-9-3 Hinata-cho, Mizuho-ku, Nagoya 467-0047, Japan

Received 15 January 2014; Revised 5 July 2014; Accepted 16 July 2014; Published 5 August 2014

Academic Editor: Jiande Chen

Copyright © 2014 Takeshi Kamiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Longstreth, W. G. Thompson, W. D. Chey, L. A. Houghton, F. Mearin, and R. C. Spiller, “Functional bowel disorders,” Gastroenterology, vol. 130, no. 5, pp. 1480–1491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Jones and S. Lydeard, “Irritable bowel syndrome in the general population,” British Medical Journal, vol. 304, no. 6819, pp. 87–90, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. A. Saito, G. R. Locke, N. J. Talley, A. R. Zinsmeister, S. L. Fett, and L. J. Melton III, “A comparison of the Rome and Manning criteria for case identification in epidemiological investigation of irritable bowel syndrome,” The American Journal of Gastroenterology, vol. 95, no. 10, pp. 2816–2824, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. W. G. Thompson, K. W. Heaton, G. T. Smyth, and C. Smyth, “Irritable bowel syndrome in general practice: prevalence, characteristics, and referral,” Gut, vol. 46, no. 1, pp. 78–82, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. W. G. Thompson, E. J. Irvine, P. Pare, S. Ferrazzi, and L. Rance, “Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire,” Digestive Diseases and Sciences, vol. 47, no. 1, pp. 225–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. P. S. Hungin, P. J. Whorwell, J. Tack, and F. Mearin, “The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects,” Alimentary Pharmacology and Therapeutics, vol. 11, no. 5, pp. 643–650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kanazawa, Y. Endo, W. E. Whitehead, M. Kano, M. Hongo, and S. Fukudo, “Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress,” Digestive Diseases and Sciences, vol. 49, no. 6, pp. 1046–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Y. Kang, “Systematic review: the influence of geography and ethnicity in irritable bowel syndrome,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 6, pp. 663–676, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. E. Lacy and R. D. Lee, “Irritable bowel syndrome: a syndrome in evolution,” Journal of Clinical Gastroenterology, vol. 39, no. 5, pp. S230–S242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. P. Weston, W. L. Biddle, P. S. Bhatia, and P. B. Miner Jr., “Terminal ileal mucosal mast cells in irritable bowel syndrome,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1590–1595, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. M. O'Sullivan, N. Clayton, N. P. Breslin et al., “Increased mast cells in irritable bowel syndrome,” Neurogastroenterology and Motility, vol. 12, no. 5, pp. 449–457, 2000. View at Google Scholar
  12. R. C. Spiller, D. Jenkins, J. P. Thornley et al., “Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome,” Gut, vol. 47, no. 6, pp. 804–811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. V. S. Chadwick, W. Chen, D. Shu et al., “Activation of the mucosal immune system in irritable bowel syndrome,” Gastroenterology, vol. 122, no. 7, pp. 1778–1783, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Barbara, V. Stanghellini, R. De Giorgio et al., “Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome,” Gastroenterology, vol. 126, no. 3, pp. 693–702, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Limsui, D. S. Pardi, M. Camilleri et al., “Symptomatic overlap between irritable bowel syndrome and microscopic colitis,” Inflammatory Bowel Diseases, vol. 13, no. 2, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. C. Spiller, “Postinfectious irritable bowel syndrome,” Gastroenterology, vol. 124, no. 6, pp. 1662–1671, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ji, H. Park, D. Lee, Y. K. Song, J. P. Choi, and S. Lee, “Post-infectious irritable bowel syndrome in patients with Shigella infection,” Journal of Gastroenterology and Hepatology, vol. 20, no. 3, pp. 381–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ghoneum, “Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (BIOBRAN),” International Journal of Immunotherapy, vol. 14, no. 2, pp. 89–99, 1998. View at Google Scholar · View at Scopus
  19. M. Ghoneum and S. Abedi, “Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran),” Journal of Pharmacy and Pharmacology, vol. 56, no. 12, pp. 1581–1588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ghoneum, “Anti-HIV activity in vitro of BIOBRAN, an activated arabinoxylan from rice bran,” Biochemical and Biophysical Research Communications, vol. 243, no. 1, pp. 25–29, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ghoneum, M. Matsuura, and S. Gollapudi, “Modified arabinoxylan rice bran (MGN-3/biobran) enhances intracellular killing of microbes by human phagocytic cells in vitro,” International Journal of Immunopathology and Pharmacology, vol. 21, no. 1, pp. 87–95, 2008. View at Google Scholar · View at Scopus
  22. H. I. Jacoby, G. Wnorowski, K. Sakata, and H. Maeda, “The effect of BIOBRAN on cisplatin and doxorubicin induced toxicity in the rat,” Journal of Nutraceuticals, Functional & Medical Foods, vol. 3, pp. 3–6, 2001. View at Google Scholar
  23. Y. Endo and H. Kanbayashi, “Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of cisplatin,” Pharmacology and Toxicology, vol. 92, no. 6, pp. 300–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Dimenas, H. Glise, B. Hallerback, H. Hernqvist, J. Svedlund, and I. Wiklund, “Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?” Scandinavian Journal of Gastroenterology, vol. 28, no. 8, pp. 681–687, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Nakazato and T. Mizuguchi, “Development and validation of Japanese version of State-Trait anxiety inventory—a study with female subjects,” Japanese Journal of Psychosomatic Medicine, vol. 22, pp. 107–112, 1982 (Japanese). View at Google Scholar
  26. A. J. Cronin, N. M. Aucutt-Walter, T. Budinetz et al., “Low-dose remifentanil infusion does not impair natural killer cell function in healthy volunteers,” British Journal of Anaesthesia, vol. 91, no. 6, pp. 805–809, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Hjemdahl, “Catecholamine measurements by high-performance liquid chromatography,” The American Journal of Physiology, vol. 247, no. 1, pp. E13–E20, 1984. View at Google Scholar · View at Scopus
  28. J. Berkes, V. K. Viswanathan, S. D. Savkovic, and G. Hecht, “Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation,” Gut, vol. 52, no. 3, pp. 439–451, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Shen and J. R. Turner, “Role of epithelial cells in initiation and propagation of intestinal inflammation: eliminating the static: tight junction dynamics exposed,” The American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 290, no. 4, pp. G577–G582, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Nobaek, M. Johansson, G. Molin, S. Ahrné, and B. Jeppsson, “Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome,” The American Journal of Gastroenterology, vol. 95, no. 5, pp. 1231–1238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Niedzielin, H. Kordecki, and B. Birkenfeld, “A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome,” European Journal of Gastroenterology and Hepatology, vol. 13, no. 10, pp. 1143–1147, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. H. J. Kim, M. Camilleri, S. McKinzie et al., “A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 7, pp. 895–904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. L. O'Mahony, J. Mccarthy, P. Kelly et al., “Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles,” Gastroenterology, vol. 128, no. 3, pp. 541–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. R. B. Sartor, “Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics,” Gastroenterology, vol. 126, no. 6, pp. 1620–1633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Shanahan, “Immunology: therapeutic manipulation of gut flora,” Science, vol. 289, no. 5483, pp. 1311–1312, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Ma, D. Wolvers, A. M. Stanisz, and J. Bienenstock, “Interleukin-10 and nerve growth factor have reciprocal upregulatory effects on intestinal epithelial cells,” The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 284, no. 5, pp. R1323–R1329, 2003. View at Google Scholar · View at Scopus
  37. D. Ma, P. Forsythe, and J. Bienenstock, “Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression,” Infection and Immunity, vol. 72, no. 9, pp. 5308–5314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. R. Snider and O. Kuchel, “Dopamine: an important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension.,” Endocrine Reviews, vol. 4, no. 3, pp. 291–309, 1983. View at Publisher · View at Google Scholar · View at Scopus
  39. B. E. Leonard, “Stress, norepinephrine and depression,” Journal of Psychiatry and Neuroscience, vol. 26, pp. S11–S16, 2001. View at Google Scholar · View at Scopus